Recent developments

at Tullis and our portfolio companies

News

Keeping you current on new and follow-on investments, portfolio product and service milestones, publications and events, management and board transitions, and other developments in Tullis funds.

October

17

Exagen Announces Appointment of John Aballi as CEO

SAN DIEGO, Oct. 17, 2022 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN) announced today that the company has...

4

Exagen Announces Appointment of Andrew L. Concoff MD, FACR, CAQSM, as Chief Innovation Officer

Dr. Concoff to lead rheumatoid arthritis medical initiatives SAN DIEGO, Oct. 04, 2022 (GLOBE NEWSWIRE) —...

11

Exagen Inc. Reports First Quarter 2022 Results

Records in Ordering Healthcare Providers and Adopters, Set All-Time Record for AVISE® CTD Monthly...

22

Exagen Inc. Expands In-Network Benefit with Additional 22.7 Million Lives

New partnership will bring total patients with in-network testing benefit to more than 90...

22

Exagen Inc. Reports Fourth Quarter and Full Year 2021 Results

Six Quarterly Records: AVISE® CTD Volume, Testing Revenue, Testing Gross Margin, Testing Gross Margin...

9

Exagen Inc. Reports Second Quarter 2021 Results

Quarterly Records: Total Revenue, AVISE® CTD Revenue and Volumes, Ordering Healthcare Providers and Adopters...

4

Exagen Inc., Allegheny Health Network Research Institute, and AHN Autoimmunity Institute Announce Collaboration to Develop Novel Patented Biomarkers into Clinical Diagnostic Tests

The suite of innovative biomarker assays seeks to further aid clinicians in the diagnosis,...

29

Exagen Inc. Announces Study on the Long-Term Effects of COVID-19 Infection in the Development of Autoimmune Diseases

Collaboration with Emory University will utilize the AVISE® testing portfolio SAN DIEGO, March 29, 2021 (GLOBE...

25

Exagen Inc. Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Gross proceeds approximately $69.1 million before underwriting discounts and commissions and other offering expenses...

22

Exagen Inc. Announces Pricing of Public Offering of Common Stock

Offering 3.7 million shares of common stock at $16.25/share SAN DIEGO, March 22, 2021 (GLOBE NEWSWIRE)...

21

Exagen Inc. Partners with Boston’s Tufts Medical Center to Offer AVISE® Testing as an In-Network Benefit for Patients Suffering from Debilitating Autoimmune Diseases

SAN DIEGO, Jan. 21, 2021 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the...

10

Exagen Inc. Reports Preliminary Fourth Quarter 2020 Testing Results

Record Testing Revenue, Adopters and AVISE CTD® Volumes SAN DIEGO, Jan. 10, 2021 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq:...

Recent developments

News

October

17

Exagen Announces Appointment of John Aballi as CEO

October

4

Exagen Announces Appointment of Andrew L. Concoff MD, FACR, CAQSM, as Chief Innovation Officer

May

11

Exagen Inc. Reports First Quarter 2022 Results

March

22

Exagen Inc. Expands In-Network Benefit with Additional 22.7 Million Lives

March

22

Exagen Inc. Reports Fourth Quarter and Full Year 2021 Results

August

9

Exagen Inc. Reports Second Quarter 2021 Results

May

4

Exagen Inc., Allegheny Health Network Research Institute, and AHN Autoimmunity Institute Announce Collaboration to Develop Novel Patented Biomarkers into Clinical Diagnostic Tests

March

29

Exagen Inc. Announces Study on the Long-Term Effects of COVID-19 Infection in the Development of Autoimmune Diseases

March

25

Exagen Inc. Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

March

22

Exagen Inc. Announces Pricing of Public Offering of Common Stock

January

21

Exagen Inc. Partners with Boston’s Tufts Medical Center to Offer AVISE® Testing as an In-Network Benefit for Patients Suffering from Debilitating Autoimmune Diseases

January

10

Exagen Inc. Reports Preliminary Fourth Quarter 2020 Testing Results